| Summary: | 碩士 === 國立中山大學 === 醫學科技研究所 === 107 === About 40,000 people are diagnosed with primary brain tumors in the United States each year, an estimated 15,000 have glioblastoma multiforme (GBM), still associated with poor prognosis with 14.6 months of median survival after surgical resection combined with chemotherapy and radiation. Preventing tumor from post-surgical recurrence is a significant clinical challenge since current methods deliver chemotherapeutic agents in a rapid manner and are not effective against the residual tumor cells, such as Gliadel® . To overcome this drawback, we develop a blue light-crosslinking hydrogel which can be rapidly gelled in situ and tightly adhere on the tissues for controlled chemotherapy, radiotherapy, and enhanced laser interstitial thermal therapy (LITT) to inhibit residual tumor cells from post-surgical recurrence. The principle goals are to i) determine the prevailing factors that affect efficient encapsulation of chemotherapeutic drugs (i.e., Epirubicin) and radio-sensitizer (i.e., Cisplatin) within hydrogels, ii) demonstrate efficiency of gelation, LITT enhancement, in vitro drug release, iii) evaluate the efficiency in human cancer cells and in vivo tumor model. Thus, we used gelatin, a highly biocompatible material which derived from collagen, as hydrogel scaffold to encapsulate small molecule drug (Epirubicin and Cisplatin). Our results have demonstrated that this multi-treatment system can effectively prevent tumor recurrence and significantly prolong the medium survival of gliosarcoma-bearing (MBR-614 or U87-MGFL) mice to above 65 days compared with the control group (36 days). We believe this synergistic strategy presents a new approach to the development of a local drug delivery system for the prevention of brain tumor recurrence.
|
|---|
